|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||315.50 - 330.85|
|52-week range||313.84 - 430.00|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||19.59|
|Forward dividend & yield||9.97 (3.15%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||N/A|
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.